Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Jianjun Zou, Gongyan Chen et al.|The Lancet Respiratory Medicine|2020Cited by 504
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyLin Shen, Jufeng Wang, Zhendong Chen et al.|Journal of Clinical Oncology|2022Cited by 306
Absence of the Adenosine A2A Receptor Confers Pulmonary Arterial Hypertension Through RhoA/ROCK Signaling Pathway in MicePing Shang, Xiaotong Wang, Zhiyong He et al.|Journal of Cardiovascular Pharmacology|2015Cited by 14
Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell lineZhiyong He, Ren-Jang Lin|Translational Cancer Research|2020Cited by 10
Association of altitude and eosinophil with the one-year mortality of acute exacerbation of chronic obstructive pulmonary disease: a cohort studyJunqing Li, Jindong Shi, Zhiyong He et al.|BMC Pulmonary Medicine|2025Cited by 2